Last reviewed · How we verify

NCT05179954: LTD

Lipoprotein Kinetics in T1D

Recruiting now NA Last updated 10 February 2026
What this trial tests

NA trial testing Metabolic testing in Type 1 Diabetes in 30 participants. Currently enrolling.

Timeline
9 May 2022
Primary endpoint
31 December 2026
31 December 2027

Quick facts

Lead sponsorUniversity of Missouri-Columbia
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment30
Start date9 May 2022
Primary completion31 December 2026
Estimated completion31 December 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Missouri-Columbia

Who can join

Adults 18 to 45, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to understand how type 1 diabetes (T1D) increases the risk for cardiovascular diseases (heart attack and stroke). To this end, the investigators will compare apolipoprotein and triglyceride kinetics in people wtih T1D and healthy control participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

Other University of Missouri-Columbia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05179954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing